Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors

Biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKis) do not always allow to achieve remission and low inflammatory activity in rheumatoid arthritis (RA), necessitating switching of therapy.
Objective: to evaluate the clinical characteristics and features of pharmacotherapy in patients with RA requiring a switch from bDMARD/JAKi.
Material and methods. The study group consisted of 103 patients with RA (85.4% women, mean age 46.9±13.7 years) who had persistent disease activity (DAS28-CRP – 5.42±0.9) despite treatment with bDMARD/JAKi or who experienced adverse events requiring therapy switching. Patients were divided into three groups: Group 1 – patients who underwent one switch (n=50), Group 2 – 2 switches (n=39), Group 3 – ≥3 switches (n=14) of bDMARD/JAKi therapy. Clinical manifestations, disease activity and pharmacotherapy were assessed.
Results and discussion. The main reason for switching therapy was ineffectiveness of bDMARD/JAKi (in 81.6% of patients). There was a tendency towards higher DAS28-ESR (p=0.052) and DAS28-CRP values (p=0.057) in groups 2 and 3 compared to group 1, as well as significant differences in CDAI (p_1–2=0.015 and p_1–3=0.011) and SDAI (p_1–2=0.013 and p_1–3=0.01). In group 3, there was a tendency towards higher DAS28-CRP, CDAI and SDAI values compared to group 2: 5.82±0.92 and 5.53±0.89; 40.5 [33.0; 45.0] and 35.2 [30.3; 43.9]; 36 [32; 42] and 32.0 [28.5; 38.5], respectively. However, these differences were statistically insignificant. Patients in groups 2 and 3 had a significantly higher number of painful joints compared to patients in group 1 (p_1–2=0.048 and p_1–3=0.036) and a significantly higher patient global assessment of disease activity (p_1–2=0.004 and p_1–3=0.013). Patients in group 3 took glucocorticoids significantly longer and at higher doses than patients in group 1. Tumour necrosis factor-α inhibitors were used more frequently in groups 1 and 2 (50.0 and 41.0%, respectively), and interleukin-6 inhibitors in group 3 (50.0%).
Conclusion. Patients with RA who required ≥2 switches of bDMARD/JAKi had higher disease activity compared to patients who required only one switch of therapy.

1. Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: the problems of remission and therapy resistance. Nauchno-prakticheskaya revmatologiya. 2018;56(3):263-271. (In Russ.).

2. Galushko EA, Gordeev AV, Matyanova EV, et al. Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results. Terapevticheskii arkhiv. 2022;94(5):661-666. (In Russ.).

3. Bobkova AO, Lila AM. Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023;17(3): 82-88. (In Russ.). doi: 10.14412/1996-7012-2023-3-82-88

4. Gordeev AV, Olyunin YuA, Galushko EA, et al. Difficult-to-treat rheumatoid arthritis. What is it? Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(5): 7-11. (In Russ.). doi: 10.14412/1996-7012-2021-5-7-11

5. Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi: 10.1136/annrheumdis2020-217344. Epub 2020 Oct 1.

6. Smolen JS. Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th Anniversary. Rheum Dis Clin North Am. 2019 Nov;45(4):477-485. doi: 10.1016/j.rdc.2019.07.001. Epub 2019 Aug 16.

7. Rubbert-Roth A, Szabу MZ, Kedves M, et al. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019 Dec;18(12):102398. doi: 10.1016/j.autrev.2019.102398. Epub 2019 Oct 19.

8. Karateev AE, Lila AM, Panevin TS, et al. Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2022;60(4):427-437. (In Russ.).

9. Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration. Ann Rheum Dis. 2022 Oct;81(10):1358-1366. doi: 10.1136/annrheumdis-2022-222586. Epub 2022 Jun 15.

10. Alten R, Burmester GR, Matucci-Cerinic M, et al. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients. Rheumatol Ther. 2023 Dec;10(6):1575-1595. doi: 10.1007/s40744-023-00597-3. Epub 2023 Sep 27.

11. Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021 Jan;80(1):96-102. doi: 10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21.

12. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 8:4:18001. doi: 10.1038/nrdp.2018.1.

13. Kim MJ, Park JW, Lee SK, et al. Treatment Sequence After Initiating Biologic Therapy for Patients With Rheumatoid Arthritis in Korea: A Nationwide Retrospective Cohort Study. J Rheum Dis. 2023 Jan 1;30(1):26-35. doi: 10.4078/jrd.22.0024. Epub 2022 Aug 30.

14. Taylor PC, Matucci Cerinic M, et al. Managing inadequate response to initial antiTNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022 Aug 16:14:1759720X221114101. doi: 10.1177/1759720X221114101.eCollection 2022.

15. Zhao SS, Kearsley-Fleet L, Bosworth A, et al. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. Rheumatology (Oxford). 2022 Nov 28;61(12):4678-4686. doi: 10.1093/rheumatology/keac190.

16. Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2010 May;22(3):321-9. doi: 10.1097/BOR.0b013e328337bd01.

17. Karpes Matusevich AR, Duan Z, Zhao H, et al. Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. Arthritis Care Res (Hoboken). 2021 Oct; 73(10):1461-1469. doi: 10.1002/acr.24358. Epub 2021 Aug 26.

18. Ebina K, Hirano T, Maeda Y, et al. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis – the ANSWER cohort study. Clin Rheumatol. 2020 Sep;39(9):2563-2572. doi: 10.1007/s10067-020-05015-5. Epub 2020 Mar 11.

19. Fujii T, Murata K, Onizawa H, et al. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. Arthritis Res Ther. 2024 Jan 9;26(1):16. doi: 10.1186/s13075-023-03251-z.

20. Conran C, Kolfenbach J, Kuhn K, et al. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management. Curr Rheumatol Rep. 2023 Dec;25(12):285-294. doi: 10.1007/s11926-023-01117-6.

21. Watanabe R, Okano T, Gon T, et al. Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems. Front Med (Lausanne). 2022 Oct 24:9:1049875. doi: 10.3389/fmed.2022.1049875.eCollection 2022.

22. Roodenrijs NMT, Welsing PMJ, van Roon J, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology (Oxford). 2022 Aug 30;61(9):3552-3566. doi: 10.1093/rheumatology/keac114.

23. Jung JY, Lee E, Kim JW, et al. Unveiling difficult-to-treat rheumatoid arthritis: longterm impact of biologic or targeted synthetic DMARDs from the KOBIO registry. Arthritis Res Ther. 2023 Sep 19;25(1):174. doi: 10.1186/s13075-023-03165-w.

24. Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther. 2022 Mar 1;24(1): 61. doi: 10.1186/s13075-022-02744-7.

25. Garcia-Salinas R, Sanchez-Prado E, Mareco J, et al. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations. Rheumatol Int. 2023 Oct; 43(10):1821-1828. doi: 10.1007/s00296-023-05349-8. Epub 2023 Jun 3.

26. Edgerton C, Frick A, Helfgott S, et al. Real-World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States. ACR Open Rheumatol. 2024 Apr;6(4):179-188. doi: 10.1002/acr2.11646. Epub 2024 Jan 14.

27. Bertsias A, Flouri ID, Repa A, et al. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis. RMD Open. 2024 Jan 19; 10(1):e003808. doi: 10.1136/rmdopen-2023-003808.